As of 2025-10-20, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is (15.83) USD. This relative valuation is based on P/E multiples. With the latest stock price at 36.81 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -143.0%.
The range of the Relative Valuation is (15.18) - (18.44) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.1x - 17.2x | 15.9x |
| Forward P/E multiples | 12.4x - 18.4x | 13.6x |
| Fair Price | (15.18) - (18.44) | (15.83) |
| Upside | -141.2% - -150.1% | -143.0% |
| Date | P/E |
| 2025-10-16 | -36.30 |
| 2025-10-15 | -35.58 |
| 2025-10-14 | -33.50 |
| 2025-10-13 | -33.77 |
| 2025-10-10 | -32.99 |
| 2025-10-09 | -33.59 |
| 2025-10-08 | -34.41 |
| 2025-10-07 | -34.04 |
| 2025-10-06 | -34.93 |
| 2025-10-03 | -33.65 |
| 2025-10-02 | -32.23 |
| 2025-10-01 | -32.61 |
| 2025-09-30 | -32.13 |
| 2025-09-29 | -31.47 |
| 2025-09-26 | -30.56 |
| 2025-09-25 | -29.49 |
| 2025-09-24 | -30.58 |
| 2025-09-23 | -30.28 |
| 2025-09-22 | -29.86 |
| 2025-09-19 | -28.59 |
| 2025-09-18 | -29.35 |
| 2025-09-17 | -27.14 |
| 2025-09-16 | -27.41 |
| 2025-09-15 | -26.71 |
| 2025-09-12 | -27.69 |
| 2025-09-11 | -27.69 |
| 2025-09-10 | -26.91 |
| 2025-09-09 | -25.83 |
| 2025-09-08 | -25.31 |
| 2025-09-05 | -27.09 |
| 2025-09-04 | -26.08 |
| 2025-09-03 | -25.90 |
| 2025-09-02 | -23.92 |
| 2025-08-29 | -20.52 |
| 2025-08-28 | -20.81 |
| 2025-08-27 | -20.30 |
| 2025-08-26 | -19.73 |
| 2025-08-25 | -19.29 |
| 2025-08-22 | -19.87 |
| 2025-08-21 | -19.33 |
| 2025-08-20 | -18.82 |
| 2025-08-19 | -18.50 |
| 2025-08-18 | -18.55 |
| 2025-08-15 | -19.11 |
| 2025-08-14 | -17.49 |
| 2025-08-13 | -18.62 |
| 2025-08-12 | -16.58 |
| 2025-08-11 | -16.03 |
| 2025-08-08 | -15.30 |
| 2025-08-07 | -14.96 |